Carrier Testing Panels for Genetic Diseases
Customize your policy alerts
Sign up for Colorado Rocky Mountain Health Plans Policy SRST2026T0586T alerts
Get alerted when Policy SRST2026T0586T changes without checking for updates manually.
Monitor payer policy activity
Defines coverage and medical necessity criteria for reproductive carrier screening panels and pan-ethnic carrier screening, and guidance for providers ordering these tests under Colorado Rocky Mountain Health Plans.
CPT code 81443 was removed from the list of applicable codes.
Description of Services, Clinical Evidence, and References sections were updated to reflect the most current information.
Medical Records Documentation Used for Reviews section was removed.
Coverage Criteria
Reproductive Carrier Screening - Covered Criteria
Covered when ALL of the following are met for specified panel sizes:
Reproductive Carrier Screening panels of up to six genes are proven and medically necessary.
Ashkenazi Jewish ancestry defined as at least one parent or grandparent of AJ descent; family history includes a biological first- or second-degree relative affected by a condition on the panel.
Not Medically Necessary
Reproductive Carrier Screening panels comprising 16 or more genes are unproven and not medically necessary.
Carrier Screening for all other indications outside the reproductive carrier screening criteria is considered unproven and not medically necessary.
Carrier screening performed for indications outside the defined reproductive carrier screening population is considered unproven and not medically necessary. The policy specifies that reproductive carrier screening panels of up to six genes are proven and medically necessary, and panels of up to 15 genes may be medically necessary when ancestry or qualifying family history criteria are met; anything beyond these reproductive screening criteria (including indications not related to reproductive risk assessment) is not covered. Carrier Screening for all other indications therefore falls outside covered criteria.
Several large cohort studies excluded individuals with a personal or family history of the disease or reported consanguinity, and many analyses used commercial testing populations that may not represent general populations. These study design features limit generalizability of reported detection rates and may produce referral or selection bias; the policy notes these limitations when considering evidence for broad panel use.
The Royal College of Obstetricians and Gynaecologists (RCOG) states there is insufficient evidence to support routine testing of all prospective parents. RCOG recommends targeted carrier screening for individuals at high risk and emphasizes that clinicians should understand the specific panel used and that interpretation should be performed by clinicians with appropriate genetics expertise.
Reproductive carrier screening panels that include 16 or more genes are considered unproven and not medically necessary due to insufficient evidence of efficacy. The policy therefore restricts coverage for larger panels and designates panels ≥16 genes as excluded from coverage.
Covered Indications
Reproductive carrier screening (preconception or prenatal) for assessing risk of autosomal recessive and X-linked conditions that may affect offspring.
Reproductive carrier screening (preconception or prenatal) for assessing risk of autosomal recessive and X-linked conditions that may affect offspring.
Carrier screening focused on individuals of Ashkenazi Jewish descent.
Carrier screening focused on individuals of Ashkenazi Jewish descent.
Preconception or prenatal carrier screening to identify carriers and at-risk couples for reproductive decision-making.
Preconception or prenatal carrier screening to identify carriers and at-risk couples for reproductive decision-making.
Individuals planning a pregnancy or pregnant individuals and their partners for carrier screening of CF, SMA, hemoglobinopathies and Tier 3 (>=1/200) conditions per ACMG/ACOG/NSGC guidance.
Individuals planning a pregnancy or pregnant individuals and their partners for carrier screening of CF, SMA, hemoglobinopathies and Tier 3 (>=1/200) conditions per ACMG/ACOG/NSGC guidance.
Not Covered
Not covered: Reproductive carrier screening panels comprising 16 or more genes and carrier screening performed for indications other than the reproductive carrier screening criteria defined in this policy. The policy requires panels beyond routinely covered sizes or outside reproductive indications to meet coverage criteria described elsewhere to be considered.
Not covered: Targeted genotyping-only panels are discouraged because they may miss pathogenic variants compared with sequencing approaches. Studies using targeted genotyping reported lower detection of some variants, and reliance on small ethnicity-based panels can fail to detect many carriers identified by pan-ethnic expanded carrier screening.
Not covered: Routine universal testing of all prospective parents is not recommended by RCOG because evidence is insufficient to support population-wide screening. Panels that are not clinically validated or lack standardization may also be discouraged; interpretation should be carried out by clinicians with appropriate genetics expertise.
Coding and Applicable Codes
| 0400U | Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative. |
| 81412 | Ashkenazi Jewish associated disorders genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1. |
| 81479 | Unlisted molecular pathology procedure |
| 81443 | CPT code removed from applicable codes |
Provider Actions and Documentation
Procedure codes and panel-size requirements
Applicable procedure codes for expanded carrier screening and related panels are listed for reference: CPT 0400U (expanded carrier screening, 145 genes, NGS), 81412 (Ashkenazi Jewish associated disorders genomic sequence analysis panel, ≥9 genes), and 81479 (unlisted molecular pathology). Panels that exceed the policy's allowable sizes (see denial risk) may be restricted or considered not medically necessary.
Justify large/sequence‑based panels
When ordering large or sequencing‑based carrier screening panels, document availability of genetic counseling resources and justify the clinical need for broad genomic testing due to potential workflow burden and low ARC yield reported in some studies.
- Document pre/post-test counseling availability (study reported median 64 minutes counselor prep time)
- Provide clinical justification for genomic sequencing–based screening given limited incremental actionable findings in some cohorts
Verify coverage and prior authorization
Verify the member’s benefit plan coverage and any prior authorization requirements with the plan before ordering carrier screening to ensure services meet member‑specific benefits and applicable mandates.
- Confirm member-specific benefit plan and any prior authorization requirements prior to testing
- Policy inclusion of codes is for reference only and does not guarantee coverage or reimbursement
Step therapy: not applicable
Not applicable — no step therapy requirements are specified in the provided policy text.
Preference for pan‑ethnic ECS vs ethnicity‑based panels
Prefer pan‑ethnic expanded carrier screening (ECS) over ethnicity‑based limited panels when clinically appropriate, as multiple studies show higher carrier detection rates with ECS compared with ethnicity‑based screening.
- ECS identified substantially more carriers and carrier couples in cohort studies vs ethnicity‑based panels
- Consider pan‑ethnic ECS especially when self‑reported ethnicity is unreliable
No additional provider action specified
(No content provided in source to populate this callout.)
Document pretest genetic counseling
Pretest genetic counseling is strongly recommended and documentation of counseling or counseling availability is advised, particularly for larger sequencing‑based panels, to inform patients of the advantages and limitations of testing.
- Document that pretest genetic counseling was provided or was available
- For large panels, note counseling resource availability due to increased follow‑up burden
Document ancestry and family history
Document accurate ancestry and family history (first‑ or second‑degree affected relatives) when relevant — coverage for panels up to 15 genes requires Ashkenazi Jewish ancestry or a biological first‑ or second‑degree relative affected by a panel condition.
- Record ancestry (e.g., Ashkenazi Jewish parent or grandparent) when claiming eligibility for up to 15‑gene panels
- Document affected biological first‑ or second‑degree relative when applicable
Check member benefits and document rationale
Before applying this policy, check the member‑specific benefit plan and any applicable federal or state mandates; the policy is informational and UnitedHealthcare may use third‑party tools in administering benefits.
- Verify member benefits and legal mandates before relying on policy for coverage decisions
- Be aware policy listings of codes are reference only and do not guarantee reimbursement
Denial risk for panels ≥16 genes
Reproductive carrier screening panels that include 16 or more genes are considered unproven and not medically necessary and may be denied; avoid ordering panels ≥16 genes without explicit medical justification and verification of coverage.
- Panels comprising 16 or more genes are listed as unproven and not medically necessary
- Orders for ≥16‑gene panels risk claim denial if not supported by applicable exceptions or prior authorization
Test selection and documentation concerns
Be aware that targeted genotyping panels and some commercial testing cohorts may miss pathogenic variants or reflect referral bias; incomplete or inaccurate ancestry/family history reporting can lead to inappropriate test selection and potential coverage denial.
- Targeted genotyping may miss pathogenic variants compared with sequencing
- Document clinical indication and ancestry/family history to support test selection and minimize risk of denial
Coding removal may affect claims
CPT code 81443 was removed from the policy’s applicable codes list; claims submitted using removed codes may be impacted and could be denied if submitted after the code’s removal date.
Eligibility Requirements
Coverage for panels up to 15 genes is conditional: the individual or their reproductive partner must have either documented Ashkenazi Jewish ancestry (at least one parent or grandparent of AJ descent) or a biological first- or second-degree relative affected by one or more of the conditions on the panel. Documentation of the qualifying ancestry or family history is required to support coverage for these panel sizes.
Some published studies specifically excluded participants with prior personal or family history of disease or prior screening; however, the policy does not mandate prior testing before expanded carrier screening. The literature shows varied inclusion criteria across cohorts, and absence of required prior testing is reflected in the policy's eligibility approach.
Multiple studies excluded individuals with a family or personal history when estimating population carrier rates; despite these exclusions, expanded carrier screening is commonly applied in clinical practice without explicit prior-testing prerequisites. The policy therefore focuses eligibility on ancestry and affected relative criteria for certain panel sizes rather than requiring prior targeted testing.
Evidence cohorts frequently excluded persons with known disease or consanguinity, and many results derive from commercial laboratory populations. These study limitations mean that clinical utility and yield observed in those cohorts may not apply to all clinical settings, and the policy does not impose prior testing requirements based solely on these studies.
Background
Carrier screening identifies asymptomatic individuals who may carry pathogenic variants for autosomal recessive or X-linked disorders that could be passed to offspring. The policy aligns with professional guidance by recommending inclusion of cystic fibrosis (CFTR) and spinal muscular atrophy (SMN1) in reproductive carrier screening panels and by defining covered panel sizes and qualifying criteria for expanded panels.
Definitions
Provider Actions — Additional Notes
Provide and document pretest genetic counseling
Pretest genetic counseling is strongly recommended to inform patients about advantages and limitations of carrier screening; document that counseling was provided or that counseling resources were offered.
- Include counseling notes or referral to genetic counseling in the record prior to testing.
No specific ordering provider restriction; ensure genetics support
The policy does not impose explicit restrictions on which provider type may order testing; however, genetic counseling is emphasized and providers should ensure appropriate counseling is available.
- If a non-genetics provider orders testing, document availability of genetics expertise for result interpretation and counseling.
Document ordering/referring provider and indication
No explicit provider‑type ordering restrictions are specified in the policy text; studies referenced included referrals from fertility specialists, obstetricians/gynecologists, and genetic counselors.
- Document referring provider and reason for referral when applicable.
Ensure ordering clinicians document counseling availability
No explicit provider‑type ordering restrictions are specified; ensure ordering clinicians document counseling resources and clinical indication when appropriate.
- Record availability of counseling and specific clinical justification for testing.
Revision History & Policy Changes
CPT code 81443 was removed from the list of applicable codes; claims submitted with that code after removal may be affected or denied.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.